Von Willebrand disease and its management in oral and maxillofacial surgery

British Journal of Oral and Maxillofacial Surgery

Volumn 36, Issue 2, 1998, Pages 112-118

  Wilde, J T ^a   Cook, R J ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; HORMONE ANALOG; VON WILLEBRAND FACTOR;

ABDOMINAL CRAMP; ARTERY THROMBOSIS; ARTICLE; DISEASE CLASSIFICATION; FLUSHING; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAXILLOFACIAL SURGERY; NAUSEA; PARTIAL THROMBOPLASTIN TIME; SUBCUTANEOUS DRUG ADMINISTRATION; TACHYCARDIA; VON WILLEBRAND DISEASE;

EID: 0031942327     PISSN: 02664356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0266-4356(98)90178-4     Document Type: Article

References (42)

1. von Willebrand EA. Hereditar pseudohemophili. Finska Lakarsallskapets Handl 1926; 67: 7-112.
2. Jaffe EA, Hoyer LW, Nachman RL. Synthesis of antihemophilic factor antigen by cultured endothelial cells. J Clin Invest 1973; 52: 2757-2764.
3. Nachman R, Levine R, Jaffe EA. Synthesis of Factor VIII antigen by cultured guinea-pig megakaryocytes. J Clin Invest 1977; 60: 914-921.
4. Hoyer LW, Shainoff JR. Factor VIII related protein circulates in normal plasma as high molecular weight multimers. Blood 1980; 55: 1056-1059.
5. Verweij A, de Vries CJM, Distel B et al. Construction of cDNA coding for human von Willebrand Factor using antibody probes for colony screening and mapping of the chromosomal gene. Nucleic Acids Res 1985; 13: 4699-4717.
6. Bonthron D, Orr EC, Mitsock LM et al. Nucleotide sequence of pre-pro-von Willebrand factor DNA. Nucleic Acids Res 1986; 14: 7125-7127.
7. Shelton-Inloes B, Titani K, Sadler J. cDNA sequences for human von Willebrand factor reveal five types of repeated domains and five possible protein sequence polymorphisms. Biochemistry 1986; 25: 3164-3171.
8. Murray EW, Lillicrap D. von Willebrand Disease: Pathogenesis, classification and management. Trans Med Revs 1996; 10: 93-110.
9. Wise RJ, Pittman DD, Handin RI et al. The propeptide of von Willebrand factor independently mediates the assembly of von Willebrand factor multimers. Cell 1988; 52: 229-236.
10. Sporn LA, Marder VJ, Wagner DD. Differing polarity of the constitutive and regulated secretory pathways for von Willebrand factor in endothelial cells. J Cell Biol 1989; 108: 1283-1289.
11. Ewenstein BM, Warhol MJ, Handin RI et al. Composition of the von Willebrand factor storage organelle (Weibel-Palade bodies) isolated from cultured human umbilical vein endothelial cells. J Cell Biol 1987; 104: 1423-1433.
12. Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells: Processing steps and their intercellular location. J Cell Biol 1984; 99: 2123-2130.
13. Cramer E, Meyer D, Menn R, Breton-Gorius J. Eccentric localization of von Willebrand factor in an internal structure of platelet alpha-granules resembling that of Weibel-Palade bodies. Blood 1985; 66: 710-713.
14. Tuddenham EGD. von Willebrand factor and its disorders: an overview of recent molecular studies. Blood Rev 1989; 3: 251-262.
15. Frederici AB, Bader R, Pagani S, Colibreti ML, de Marco C, Mannuci PM. Binding of von Willebrand factor to glycoprotein Ib and IIb/IIIa complexes. Affinity is related to multimer size. Br J Haematol 1989; 73: 93-99.
16. Sixma JJ, Sakariassen KJ, Beeser-Visser NH, Ottenhof-Rovers M, Bolhuis PA. Adhesion of platelet to human artery subendothelium: effect of factor VIII von Willebrand factor of various multimeric composition. Blood 1984; 63: 128-139.
17. Ruggeri ZM. von Willebrand factor and platelets in hemostasis. Haemophilia 1996; 2(Suppl 1): 2.
18. Holmberg L, Nilsson IM. von Willebrand Disease. Clin Haematol 1985; 14: 461-488.
19. Sadler EJ. A revised classification of von Willebrand disease. Thromb Haemostas 1994; 71: 520-525.
20. Mazurier C. Molecular genetics of von Willebrand disease. Symposia presentation XXII International Congress of the World Federation of Hemophilia, Dublin 1996. Haemophilia 1996; 2(Suppl 1): 9.
21. Ginsburg D, Sadler JE. von Willebrand disease: A database of point mutations, insertions and deletions. Thromb Haemost 1993; 69: 177-184.
22. Nishino M, Girma J-P, Rothschild C, Fressinaud E, Meyer D. New variant of von Willebrand disease with defective binding to factor VIII. Blood 1989; 74: 1591-1599.
23. Keila S, Kaufman A, Itckowitch D. Uncontrolled bleeding during endodontic treatment as the first symptoms for diagnosing von Willebrand's disease. A case report. Oral Surg Oral Med Oral Pathol 1990; 69: 243-246.
24. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. DDAVP: a new pharmacological approach to the management of haemophilia and von Willebrand's disease. Lancet 1977; i: 869-872.
25. Aledort LM. Treatment of von Willebrand's disease. Mayo Clin Proc 1991; 66: 841-846.
26. Petrover, MG, Cohen CI. The use of desmopressin in the management of two patients with von Willebrand's disease undergoing periodontal surgery. Two case reports. J Periodont 1990; 61: 239-242.
27. Rodeghiero F, Castaman G, Di Bona E, Ruggeri M. Consistency with responses to repeated DDAVP infusions in patients with von Willebrand's disease and haemophilia A. Blood 1989; 74: 1997-2000.
28. Abildegaard CF, Suzuki Z, Harrison J, Jeffcoate K, Zimmerman TS. Serial studies in von Willebrand's disease: variability versus 'variants'. Blood 1980; 56: 712-716.
29. De la Fuente B, Kaspar CK, Rickles FR, Hoyer LW. Response of patients with mild and moderate haemophilia A and von Willebrand's disease to treatment with desmopressin. Ann Intern Med 1985; 103: 6-14.
30. Gralnick HR, Williams SB, McKeown LP et al. DDAVP in type IIA von Willebrand's disease. Blood 1986; 67: 465-468.
31. Mazurier C, Gaucher C, Jorieux S et al. Biological effect of desmopressin in eight patients with type 2N (Normandy) von Willebrand disease. Br J Haematol 1994; 88: 849-854.
32. Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 1992; 82: 87-93.
33. Mannucci PM, Vicente V, Alberca I et al. Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and Factor VIII responses. Thromb Haemost 1987; 58: 1037-1039.
34. Lethagen S, Harris AS, Sjorin E, Nilsson IM. Intranasal and intravenous administration of desmopressin: effect on FVIII/vWF, pharmacokinetics and reproducibility. Thromb Haemost 1987; 58: 1033-1036.
35. Lethagen S. Self-treatment with desmopressin intranasal spray in patients with bleeding disorders: effect on bleeding symptoms and socioeconomic factors. Ann Hematol 1993; 66: 257-260.
36. Rodeghiero F, Castaman G, Mannucci PM. Clinical indications for desmopressin (DDAVP) in congenital and acquired von Willebrand disease. Blood Rev 1991; 5: 155-161.
37. United Kingdom Haemophilia Centre Directors Organisation Executive Committee. Guidelines on therapeutic products to treat haemophilia and other hereditary coagulation disorders. Haemophilia 1997; 3: 63-77.
38. Cumming AM, Fildes S, Cumming IR, Wensley RT, Redding OM, Burn AM. Clinical and laboratory evaluation of National Health Service factor VIII concentrate (8Y) for the treatment of Von Willebrand's disease. Br J Haematol 1990; 75: 234-239.
39. Berntorp E, Nilsson IM. Use of a high purity factor VIII concentrate (Hemate P) in Von Willebrand's disease. Vox Sang 1989; 56: 212-217.
40. Martinowitz U, Schulman S. Fibrin sealant in surgery of patients with a hemorrhagic diathesis. Thromb Haemost 1995; 74: 486-492.
41. Vaughan ED. The maxillofacial surgeon and cranial base surgery. Br J Oral Maxillofac Surg 1996; 34: 4-17.
42. Ilankovan V, Blesing NE, Moos KF, Davidson JF. Correction of facial deformities in patients with mild bleeding disorders: a report of three cases. Br J Oral Maxillofac Surg 1990; 28: 398-400.